Navigation Links
InspireMD Becomes a Supporting Organization in the Growing Stent for Life Initiative
Date:8/30/2010

InspireMD Becomes a Supporting Organization in the Growing Stent for Life Initiative -- STOCKHOLM, August 30, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Pharmaceuticals, Joint Ventures, New Products & Services Click to view news release full screen  

InspireMD Becomes a Supporting Organization in the Growing Stent for Life Initiative

 

STOCKHOLM, August 30, 2010 /PRNewswire/ --

- The Stent for Life Initiative (SFL) Celebrates its First Year Anniversary as the ESC 2010 Congress in Stockholm, Monday August 30th

InspireMD Ltd., a medical device company engaged in the development and commercialization of MGuard(TM) novel stent systems, is happy to announce that it has joined the Stent for Life Initiative as a supporting organization. The Stent for Life Initiative aims to improve the delivery and patient access to the life saving indications of PCI and thereby reduce the mortality and morbidity of patients suffering from acute coronary syndromes.

InspireMD, Ltd., is a medical device company, that engages in the development and commercialization of MGuard, a novel net protective stent system that is specifically designed to treat thrombus loaded lesions in the cases of acute coronary syndrome, acute myocardial infarction, or saphenous vein grafts. "We are delighted to become part of the SFL initiative," stated Mr. Ofir Paz, CEO at InspireMD. "We are convinced that increasing the use of primary PCI in STEMI patients is the most important advancement in our field today and we focus our efforts on providing the best products and solutions to support this noble initiative."

Stent for Life was initiated one year ago during the European Association of Percutaneous Cardiovascular Interventions (EAPCI) General Assembly at the ESC Congress 2009 in Barcelona. The Initiative is a unique European platform for interventional cardiologists, government representatives, industry partners, patient groups and patients to work together and, by shaping the health care systems and medical practices, ensure that the majority of ST elevation myocardial infarction (STEMI) patients will have an equal access to the life saving indication of percutaneous coronary intervention (PCI).

Industry partners, such as InspireMD, sign up because they are willing to actively support the project goals. This support may include participating in defining strategy, as well as providing expertise such as project management, local analysis, patient awareness, promotion, funding and investment planning.

Join the Stent for Life Declaration signature ceremony at ESC 2010. The Stent for Life Initiative will celebrate its first year anniversary at ESC 2010 Congress in Stockholm. The ceremony will take place as a continuation of the EAPCI General Assembly on Monday 30 August, 16:30 - 18:00. Meet the SFL family members to learn about Initiatives' first year achievements

About MGuard(TM) Coronary

MGuard(TM) presents a novel combination of a coronary stent merged with an embolic protection. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The MGuard(TM) coronary stent provides permanent embolic protection, without complicating deliverability. MGuard(TM) is CE Mark approved. The MGuard(TM) Coronary's innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world.

About InspireMD

InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: restenosis, embolic showers, and late thrombosis. In addition to providing embolic protection and minimizing arterial injury, this promising technology can be an effective and uniform drug delivery mechanism with the help of the novel micron-level net for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures.

About Stent for Life:

There is indisputable scientific evidence that myocardial revascularization in patients with acute forms of coronary artery disease is life saving; it reduces mortality, rates of non-fatal reinfarction and stroke, as compared to the previous standard of care (pharmacological treatment, including thrombolytic therapy for STEMI).

The Stent for Life Initiative is a unique European platform for interventional cardiologists, government representatives, industry partners, patient groups and patients to work together and, by shaping the health care systems and medical practices, ensure that the majority of STEMI patients will have an equal access to the life saving indication of PCI.

The executive board is: Prof. Petr Widimsky, Co-Chairman; Dr. Jean Fajadet, Co-Chairman; Dr. William Wijns; Prof. Carlo di Mario; Prof. Nicolas Danchin; Prof. Steen D. Kristensen; Dr. Zuzana Kaifoszova; Marielle de la Torre.

The participating organizations are: EAPCI, EuroPCR, the ESC Working Group on Acute Cardiac Care and the National Cardiology Societies and/or National Working Groups for Interventional Cardiology (WGIC)

The current member countries are: Egypt, Italy, Romania, Bulgaria, France, Greece, Serbia, Spain and Turkey.

The industry partners are: Abbott Vascular, Biotronik, Boston Scientific, Cordis Johnson & Johnson, Eli Lilly,

IHT-Cordynamics, InspireMD, Medtronic, Philips Healthcare, Terumo Europe and The Medicines Company.

Contact details: http:// www.inspire-md.com Jonina Ohayon Marketing Director jonina@inspire-md.com mobile: +972-52-5791120 http://www.stentforlife.com Zuzana Kaifoszova, M.D., MBA Stent for Life Initiative Project Manager, Europe kaifosz@gmail.com Mobile: +420-724-547-303
'/>"/>

SOURCE Inspire MD
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. For the First Time, at EuroPCR, InspireMD Will Provide a Sneak Preview of the Next Generation MGuard Prime(R), a State of the Art Net Protective Cobalt Chromium Stent System
2. InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
3. As Pharmaceutical Deal Making Becomes More Competitive, PharmaDeals(R) Resource Expands its Deal Coverage
4. Novocell Becomes ViaCyte, Inc., as it Accelerates Pre-Clinical Development of a Stem Cell Derived Treatment for Diabetes
5. Pfizers Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts
6. Missouri Becomes the Fourth State to Connect to Kentuckys Real-time Cold Medicine Tracking System
7. Mount Vernon Cancer Centre Becomes First NHS Facility to Acquire a CyberKnife System
8. US Oncology Foundation Becomes Life Beyond Cancer Foundation
9. Sigma-Aldrich Becomes the Sole U.S. and Canada Distributor of Kromasil(R) HPLC Columns Through Agreement With Eka Chemicals
10. CVS Caremarks MinuteClinic Becomes First Retail Clinic Provider to Achieve Consecutive Accreditation Awards From The Joint Commission
11. Hope International Centro de Radioterapia of Guatemala Becomes First in Latin America to Treat Cancer Using RapidArc(R) Radiotherapy Technology From Varian Medical Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Dublin ... the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global market ... its applications in various applications. The report deals with ... main industries: pharmaceutical and biotechnology, food and beverage, and ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
Breaking Medicine News(10 mins):